⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Reunion Neuroscience and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Reunion Neuroscience
↗Morristown, New Jersey, USA
Reunion Neuroscience is a clinical-stage biopharmaceutical company dedicated to developing next-generation, psychedelic-inspired therapeutic solutions for underserved mental health disorders. The company focuses on creating fast-acting, short-duration therapies to address significant unmet needs in conditions such as postpartum depression (PPD), adjustment disorder, and generalized anxiety disorder.
Formerly known as Field Trip Health Ltd., the company has pivoted its strategy to focus on proprietary drug development, specifically its lead asset, luvesilocin (RE104), a serotonergic psychedelic prodrug. The company is venture-backed and maintains a strong focus on clinical-stage research, with recent milestones including Breakthrough Therapy Designation from the FDA for its lead candidate.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$233M
Investors:Novo Holdings
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (advancing to Phase 3)
Modalities:Small molecule
Active Trials:5
Trial Phases:Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Precision AQ (IR/PR support)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Greg Mayes - CEO
Mark Pollack - CMO
Edward Smith - CFO
Board Members:Fred Grossman
LINKS
Website:reunionneuro.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Reunion Neuroscience. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.